Docetaxel plus ramucirumab (DR) versus docetaxel plus placebo (D) as second-line treatment for advanced non-small cell lung cancer (NSCLC): A randomized, phase II, double-blind, multicenter trial in Japan.

被引：0
|
作者：
Hosomi, Yukio
Yoh, Kiyotaka
Kasahara, Kazuo
Yamada, Kazuhiko
Takahashi, Toshiaki
Tanaka, Kaoru
Hida, Toyoaki
Yoshioka, Hiroshige
Kato, Terufumi
Takeda, Koji
Nishio, Makoto
Sakai, Hiroshi
Maemondo, Makoto
Takenoyama, Mitsuhiro
Nokihara, Hiroshi
Tatsumi, Masumi
Nakamura, Takashi
Enatsu, Sotaro
Tamura, Tomohide
Nakagawa, Kazuhiko
机构：
[1] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan
[2] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan
[3] Kanazawa Univ, Grad Sch Med Sci, Dept Resp Med, Cellular Transplantat Biol, Kanazawa, Ishikawa, Japan
[4] Kurume Univ, Sch Med, Kurume, Fukuoka 830, Japan
[5] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[6] Kiniki Univ, Fac Med, Osaka, Japan
[7] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi 464, Japan
[8] Kurashiki Cent Hosp, Kurashiki, Okayama, Japan
[9] Kanagawa Cardiovasc & Resp Ctr, Yokohama, Kanagawa, Japan
[10] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan
[11] Japanese Fdn Canc Res, Tokyo, Japan
[12] Saitama Canc Ctr, Saitama, Japan
[13] Miyagi Canc Ctr, Sendai, Miyagi, Japan
[14] Kyushu Canc Ctr, Natl Hosp Org, Fukuoka, Japan
[15] Natl Canc Ctr, Tokyo, Japan
[16] Eli Lilly Japan, Kobe, Hyogo, Japan
[17] Lilly Res Labs Japan, Kobe, Hyogo, Japan
[18] St Lukes Int Hosp, Tokyo, Japan
[19] Kinki Univ, Fac Med, Osakasayama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8054
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    J. Feliu
    G. Martín
    J. Castro
    A. Sundlov
    A. Rodriguez-Jaráiz
    E. Casado
    M. Lomas
    C. Madroñal
    A. Galán
    C. Belda
    M. Gonzalez-Barón
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
  • [42] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    Feliu, J.
    Martin, G.
    Castro, J.
    Sundlov, A.
    Rodriguez-Jaraiz, A.
    Casado, E.
    Lomas, M.
    Madronal, C.
    Galan, A.
    Belda, C.
    Gonzalez-Baron, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 527 - 531
  • [43] A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer
    Jones, Suzanne
    Thompson, Dana
    Barton, John
    Patton, Jeff
    Shipley, Dianna
    Greco, E. Anthony
    Spigel, David
    Infante, Jeff
    Burris, Howard A., III
    CLINICAL LUNG CANCER, 2008, 9 (03) : 154 - 159
  • [44] Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study
    Fang, Y.
    Pan, H.
    Shou, J.
    Hong, W.
    Yang, X.
    Zhu, D.
    Zhou, Y.
    Lan, F.
    Rao, C.
    Chen, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S682 - S682
  • [45] Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
    Boer, Katalin
    Lang, Istvan
    Llombart-Cussac, Antonio
    Andreasson, Inger
    Vivanco, Guillermo L.
    Sanders, Nick
    Pover, Gillian M.
    Murray, Elizabeth
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 681 - 687
  • [46] Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study
    Katalin Boér
    István Láng
    Antonio Llombart-Cussac
    Inger Andreasson
    Guillermo L. Vivanco
    Nick Sanders
    Gillian M. Pover
    Elizabeth Murray
    Investigational New Drugs, 2012, 30 : 681 - 687
  • [47] Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo controlled, randomized phase II study.
    Boer, K.
    Lang, I
    Llombart-Cussac, A.
    Andreasson, I
    Vivanco, G. L.
    Sanders, N.
    Paver, G. M.
    Murray, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S274 - S274
  • [48] Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
    Choueiri, Toni K.
    Ross, Robert W.
    Jacobus, Susanna
    Vaishampayan, Ulka
    Yu, Evan Y.
    Quinn, David I.
    Hahn, Noah M.
    Hutson, Thomas E.
    Sonpavde, Guru
    Morrissey, Stephanie C.
    Buckle, Geoffrey C.
    Kim, William Y.
    Petrylak, Daniel P.
    Ryan, Christopher W.
    Eisenberger, Mario A.
    Mortazavi, Amir
    Bubley, Glenn J.
    Taplin, Mary-Ellen
    Rosenberg, Jonathan E.
    Kantoff, Philip W.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) : 507 - 512
  • [49] The efficacy and safety profile of anlotinib plus docetaxel as second-line treatment in advanced non-small cell lung cancer.
    Xu, Zhiqiao
    Zhang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer
    Soria, J. -C.
    Fueloep, A.
    Maciel, C.
    Fischer, J. R.
    Girotto, G.
    Lago, S.
    Smit, E.
    Ostoros, G.
    Eberhardt, W. E. E.
    Lishkovska, P.
    Lovick, S.
    Mariani, G.
    McKeown, A.
    Kilgour, E.
    Smith, P.
    Bowen, K.
    Kohlmann, A.
    Carlile, D. J.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3028 - 3036
12345